by Cancer Immunology, Immunotherapy
Scientists believe prostaglandin F2 receptor negative regulator (PTGFRN) is a possible target for chimeric antigen receptor (CAR) T-cell therapy in patients with glioblastoma (GBM).
by Blood Advances
Researchers report the safety of a novel approach to insulate edited cells from chimeric antigen receptor (CAR) selection and attack.
by ASTCT Talks
In a special co-branded episode between Oncology On theGo hosted by CancerNetwork® and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Nora...
by Blood Advances
Phase II evidence supports the use of post-transplant cyclophosphamide (PTCy) as prophylaxis against acute graft-versus-host disease (aGVHD) in patients undergoing hematopoietic cell...
by Blood Advances
Study data suggest donor age and HLA status influence outcomes in older patients receiving post-transplant cyclophosphamide as graft-versus-host disease prophylaxis following hematopoietic cell...
This live session will focus on two core topics in the field - CAR T and Gene Therapy. The faculty below will briefly present slides on their topic, and then answer questions and share their...